AbbVie Pre-Paid Expenses 2010-2024 | ABBV

AbbVie pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
  • AbbVie pre-paid expenses for the quarter ending September 30, 2024 were $4.717B, a 3.9% increase year-over-year.
  • AbbVie pre-paid expenses for 2023 were $4.932B, a 12.07% increase from 2022.
  • AbbVie pre-paid expenses for 2022 were $4.401B, a 11.86% decline from 2021.
  • AbbVie pre-paid expenses for 2021 were $4.993B, a 40.17% increase from 2020.
AbbVie Annual Pre-Paid Expenses
(Millions of US $)
2023 $4,932
2022 $4,401
2021 $4,993
2020 $3,562
2019 $2,354
2018 $1,895
2017 $4,741
2016 $3,562
2015 $1,458
2014 $1,952
2013 $1,234
2012 $1,320
2011 $543
2010 $489
2009 $
AbbVie Quarterly Pre-Paid Expenses
(Millions of US $)
2024-06-30 $4,717
2024-03-31 $4,608
2023-12-31 $4,932
2023-09-30 $4,541
2023-06-30 $4,540
2023-03-31 $4,460
2022-12-31 $4,401
2022-09-30 $4,570
2022-06-30 $4,506
2022-03-31 $4,721
2021-12-31 $4,993
2021-09-30 $4,333
2021-06-30 $4,099
2021-03-31 $3,932
2020-12-31 $3,562
2020-09-30 $3,169
2020-06-30 $2,803
2020-03-31 $2,410
2019-12-31 $2,354
2019-09-30 $2,060
2019-06-30 $2,307
2019-03-31 $1,803
2018-12-31 $1,895
2018-09-30 $2,114
2018-06-30 $2,729
2018-03-31 $3,391
2017-12-31 $4,741
2017-09-30 $2,700
2017-06-30 $3,316
2017-03-31 $3,195
2016-12-31 $3,562
2016-09-30 $1,711
2016-06-30 $1,985
2016-03-31 $1,480
2015-12-31 $1,458
2015-09-30 $1,148
2015-06-30 $1,381
2015-03-31 $1,050
2014-12-31 $1,952
2014-09-30 $1,705
2014-06-30 $1,585
2014-03-31 $1,460
2013-12-31 $1,234
2013-09-30 $558
2013-06-30 $626
2013-03-31 $711
2012-12-31 $1,320
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $543
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $308.242B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48